ANI Pharmaceuticals Inc. has acquired the new drug applications (NDAs) for Oxistat Lotion, Veregen Ointment, and Pandel Cream and the abbreviated new drug application (ANDA) for ApexiCon E Cream from Sandoz Inc. Pandel Cream will be transitioned later upon receiving the requisite approvals.   Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company’s pre-existing revolver credit facility.   In conjunction with t...